Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index (AMEX:RSY)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index Charts. Click Here for more Merrill Lynch & Co. Strategic Return Notes Linked TO The Select 10 Index Charts.](/p.php?pid=staticchart&s=A%5ERSY&p=8&t=15)
Recom Managed Systems (AMEX: RSY) announced today that
it has chosen Ventura, Calif.-based Ventrex, Inc. as its
contract-manufacturing partner. Ventrex exclusively manufactures
medical devices and has Fortune 100 companies among its clients.
Ventrex has produced a wide range of medical products and has
experience in producing monitoring devices that are similar to Recom's
Model 100 in function and design.
"The agreement with Ventrex to serve as our contract manufacturer
is an important milestone for Recom," said Rod Hildebrandt, chief
operating officer of Recom. "We were very diligent in our search for a
manufacturer because it was important to us to find a quality
organization like Ventrex with which we could partner for the long
term. We are excited to begin the commercial production of the Recom
Model 100."
"We are pleased and honored to be selected as Recom's partner in
the manufacture of their very promising new product," said Bob
Guthrie, general manager of Ventrex. "The technology employed in this
unique device fits well with our core capabilities. We are confident
that this will be a long and mutually beneficial relationship."
Ventrex is privately owned by its on-site management team, who
have more than 20 years of experience in all facets of medical-device
manufacturing. Ventrex's manufacturing facility is FDA-approved and
ISO 13485-certified. The company has experienced seven years of steady
growth while establishing a very impressive track record of producing
high-quality products at competitive costs, and their on-time delivery
rate is more than 98 percent.
Recom and Ventrex have jointly initiated component part
acquisition in order to commence production of the Model 100 as soon
as practicable and definitely toward the end of the current calendar
quarter.
About Recom Managed Systems, Inc.
Recom Managed Systems, Inc. is an emerging life-sciences company
focused on the monitoring and detection of disease through continuous
biomedical signal monitoring. Recom Managed Systems, Inc. uses its
patented signal technology to design and develop medical devices that
simplify and reduce the costs of diagnostic testing and patient
monitoring in an ambulatory setting. With its patented
signal-technology platform, Recom brings clinical-quality
physiological signal monitoring to the ambulatory setting.
Recom's first product, the Model 100 Heart Monitor, is an
ambulatory patient heart monitor that uses patented signal-processing
technology to record a clinical-quality ECG signal in the presence of
interference generated by the patient's body movements and ambient
environment. The Model 100 has received 510(k) clearance from the Food
and Drug Administration.
Recom Managed Systems, Inc. is traded on the American Stock
Exchange under the symbol RSY. More information is located at
http://www.recom-systems.com
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are
"forward-looking" statements. Forward-looking statements involve known
and unknown risks, which may cause Recom's actual results in the
future to differ materially from expected results. Factors which could
cause or contribute to such differences include, but are not limited
to, failure to complete the development and introduction of new
products or services, failure to obtain federal or state regulatory
approvals governing medical devices, monitoring and other related
services or products, inability to obtain physician, patient or
insurance acceptance of Recom's products or services, adverse
equity-market conditions and declines in the value of Recom's common
stock, and the unavailability of financing to complete management's
plans and objectives. These risks are qualified in their entirety by
cautionary language and risk factors set forth and to be further
described in Recom's filings with the Securities and Exchange
Commission.